Amgen presents thorough analysis of the study data at ASCO PEAK -
Amgen (NASDAQ: AMGN) today announced the results of the study Phase 2 PEAK that reinforce improved overall survival (OS) benefit of panitumumab (Vectibix ® ) when used in combination with FOLFOX, chemotherapy oxaliplatin compared to bevacizumab (Avastin ® ) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC). The data were presented today at the 50 e Annual Meeting of American Society of Clinical Oncology (ASCO) in Chicago (Abstract No. 3629).
The data presented at ASCO was an extensive analysis of the study PEAK that supports the use of panitumumab in combination with FOLFOX for patients with wild-type RAS (absence of exons 2, 3, or 4 KRAS or NRAS mutations) mCRC.
In this exploratory analysis, patients who received panitumumab plus FOLFOX and were then treated with a treatment based inhibitor of VEGF (including bevacizumab) had an improved median OS 41.3 months. By comparison, patients who received bevacizumab plus FOLFOX and were then treated with a treatment with anti-EGFR inhibitor (including panitumumab / cetuximab), had improved median overall survival of 29.0 months. In both arms, the results were similar to those observed in the overall population treated with wild-type RAS mCRC.
"Initial PEAK data reinforce the potential importance of panitumumab for some patients, but we wanted to assess whether the benefit was dependent administration with FOLFOX and whether other subsequent treatments could affect results survival, "said Fernando Rivera, MD, Department of medical oncology, Hospital Universitario Marques de Valdecilla, Santander, Spain, and a principal investigator in the study." These data suggest that a first-line treatment strategy with panitumumab in combination with FOLFOX may offer clinical benefit in patients with wild-type RAS metastatic colorectal cancer compared with regimens containing bevacizumab in this setting process. "
" the study PEAK not only shows panitumumab survival benefit in patients with metastatic colorectal cancer wild type KRAS tumors, but also brings us a step closer to understanding the genetic markers how unique can change the way we treat cancer, "said Sean E. Harper, MD, executive vice president of research and development at Amgen. "All the studies we conduct as part of our comprehensive development program panitumumab adds to a better understanding of how to customize care for patients with cancer."
Colorectal cancer is the third most common cancer in the United States, and is the second leading cause of cancer death. Approximately 1.2 million cases of colorectal cancer are expected to occur in the world.
EmoticonEmoticon